デフォルト表紙
市場調査レポート
商品コード
965024

ヒドロキシクロロキン薬市場-成長、動向、および予測(2022年~2027年)

Hydroxychloroquine Drugs Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

出版日: | 発行: Mordor Intelligence Pvt Ltd | ページ情報: 英文 111 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=136.22円
ヒドロキシクロロキン薬市場-成長、動向、および予測(2022年~2027年)
出版日: 2022年01月17日
発行: Mordor Intelligence Pvt Ltd
ページ情報: 英文 111 Pages
納期: 2~3営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

世界のヒドロキシクロロキン薬の市場規模は、予測期間中に約16.8%のCAGRで拡大すると予測されています。ヒドロキシクロロキンは、クロロキンのより安全な誘導体です。ヒドロキシクロロキンは、マラリアの治療または予防に適応される免疫抑制および抗寄生虫薬ですが、この薬はクロロキン耐性マラリアには効果がありません。ヒドロキシクロロキンは、全身性および円板状エリテマトーデスなどの自己免疫疾患や、他の薬剤が効かない、または使用できない関節リウマチ(急性および重度)にも推奨されます。広域スペクトルのヒドロキシクロロキン薬は、さまざまなウイルスの治療に使用できます。中国の科学技術省によると、ヒドロキシクロロキンは、初期の臨床試験でコロナウイルスをブロックするための有望なプロファイルを示した薬の1つです。

最近、ヒドロキシクロロキンはコロナウイルス(COVID19)の患者の治療に有効であるため注目されています。中国からの報告では、クロロキンが試験管内でSARS-CoV-2を阻害する可能性があることを実証しました。この薬は、コロナウイルス患者の治療に高い有効性があることを示唆しています。ヒドロキシクロロキンは、コロナウイルスの有望な潜在的治療法となると期待されています。米国食品医薬品局(FDA)は、コロナウイルス(COVID19)を治療するための緊急使用のためにヒドロキシクロロキンを指定しました。

新規のヒドロキシクロロキンの需要の増加とジェネリック医薬品の浸透は、市場に大きく成長させると予測されています。たとえば、2020年3月、Novartis International AGは、コロナウイルスの検査で陽性となった人々におけるヒドロキシクロロキンの有効性を評価するための管理された臨床試験をするため、米国保健社会福祉省(HHS)に3000万回分のヒドロキシクロロキン錠剤の出荷を開始しました。さらに、製品の承認が増えると、政府の資金が増えるため、市場に強く浸透するとみられています。

COVID-19に関する患者の意識の高まりと、世界の舞台での新しいジェネリック医薬品の流入により、ヒドロキシクロロキン薬の採用が加速すると予測されています。ジョンズホプキンス大学によると、2020年4月15日の時点で、米国だけで約609,516人がCOVID-19に罹患しています。病気の治療に関する意識の高まり、COVID-19の治療におけるヒドロキシクロロキンの有効性を評価するための臨床試験の増加は、収益を拡大させると推定されています。ただし、低所得国でのヘルスケアへのアクセスの悪さは、市場の成長を抑制する可能性があります。

当レポートでは、ヒドロキシクロロキン薬市場について調査し、市場の概要とともに、用途別、流通チャネル別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場の推進力
    • コロナウイルス(COVID 19)などの病気の発生
    • マラリアと関節リウマチの高い有病率
    • 製品の発売と承認の増加
    • さまざまな治療条件におけるヒドロキシクロロキンの用途拡大
  • 市場の抑制要因
    • ヒドロキシクロロキンの世界の不足
    • 低所得国におけるヘルスケアのアクセシビリティの低さ
  • ポーターのファイブフォース分析

第5章 市場セグメンテーション

  • 用途別
    • コロナウイルス(COVID-19)
    • マラリア
    • エリテマトーデス
    • 関節リウマチ
  • 流通チャネル別
    • オンライン薬局
    • 院内薬局
    • 小売薬局
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • DR. REDDY'S LABORATORIES LTD
    • Laurus Labs Limited,
    • Lupin
    • Mylan NV
    • Novartis International AG
    • Sanofi SA
    • Sun Pharmaceutical Industries Ltd
    • Teva Pharmaceuticals USA Inc.
    • Zydus Pharmaceuticals

第7章 市場機会と将来動向

目次
Product Code: 69353

The global hydroxychloroquine drugs market studied was anticipated to register a CAGR of nearly 16.8% during the forecast period. Hydroxychloroquine is a safer derivative of chloroquine. Hydroxychloroquine is an immunosuppressive and anti-parasite drug indicated for the treatment or prevention of malaria, although the drug is ineffective for chloroquine-resistant malaria. Hydroxychloroquine is also recommended for autoimmune diseases such as systemic and discoid lupus erythematosus, and rheumatoid arthritis (acute and severe) when other medications fail to work or cannot be used. Broad-spectrum hydroxychloroquine drugs can be used to treat a range of viruses. According to China's Ministry of Science and Technology, hydroxychloroquine is one of the drugs which demonstrated encouraging profile for blocking coronavirus in early clinical trials.

Recently, hydroxychloroquine has attracted attention due to its effectiveness in treating patients with coronavirus disease (COVID 19). Reports from China demonstrated chloroquine could possibly inhibit SARS-CoV-2 in vitro. The drug showed high efficacy in treating the patients with coronavirus disease (COVID 19). Hydroxychloroquine is expected to be a promising potential treatment for the coronavirus disease (COVID 19). The US Food and Drug Administration (FDA) designated hydroxychloroquine for emergency use for treating coronavirus disease (COVID 19).

Increasing demand for novel hydroxychloroquine and rising penetration of generic drugs are estimated to provide a significant boost to the market. For instance, in March 2020, Novartis International AG started the shipping of 30 million doses of hydroxychloroquine tablets to the US Department of Health and Human Services (HHS) for controlled clinical studies to evaluate the effectiveness of hydroxychloroquine in people who have tested positive for coronavirus disease (COVID 19). In addition, increasing product approval is poised to have strong market penetration due to the presence of increased government funding.

Growing patient awareness regarding COVID-19 and the influx of new generics in the global arena are projected to accelerate the adoption of hydroxychloroquine drugs. As per the Johns Hopkins University, as of 15th April 2020, approximately 609,516 people suffered from COVID-19 in the US alone. Increasing awareness regarding disease remittance therapies, rising clinical trials to evaluate the effectiveness of hydroxychloroquine in the treatment of COVID-19 are estimated to promote revenue growth. However, poor healthcare accessibility in low-income countries may restrain the growth of the market.

Key Market Trends

Rheumatoid Arthritis Dominates the Market and is Expected to Continue to Do the Same during the Forecast Period

  • Rheumatoid arthritis is expected to dominate the global hydroxychloroquine drugs market through the forecast period. This can be attributed to the rising prevalence of rheumatoid arthritis, which causes different symptoms, such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient's mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and the risk of joint replacement.
  • According to the World Health Organization, more than 23 million people live with rheumatoid arthritis. Thus, the rheumatoid arthritis segment is witnessing a shift toward combination therapies that provide enhanced results to patients. Higher availability, positive results, and low price of generic drugs for the target disease are supplementing the growth of the segment.
  • Moreover, COVID-19 is estimated to be the fastest-growing segment over the forecast period. Exponentially increasing cases worldwide is the major factor expected to drive the vertical over the forecast period. The World Health Organization declared coronavirus disease (COVID 19) as a pandemic on March 11, 2020. As per the Johns Hopkins University, till the date April 15, COVID-19 is responsible for more than 126,859 deaths worldwide. Hydroxychloroquine is expected to be a promising potential treatment for the coronavirus disease (COVID 19). The US Food and Drug Administration (FDA) designated hydroxychloroquine for emergency use for treating coronavirus disease (COVID 19). All the aforementioned factors expected to bode a well for this vertical.

North America Represents the Largest Market and Asia-Pacific is Expected to Register Fastest Growth.

North America is at the forefront of growth in the region and is also an important revenue contributor in the global arena. Heightened awareness of disease remittance therapies among patients, rising prevalence of RA and COVID-19, and high public and private healthcare spending are stimulating the growth of the region. Moreover, the World Health Organization estimates that by the end of 2040, 54.4 million adults in the country may suffer from rheumatoid arthritis. Moreover, easy access to quality healthcare, favorable reimbursement policies, strong clinical pipeline, and approval of novel drugs are projected to promote revenue growth in North America.

Asia-Pacific is likely to post the fastest market throughout the forecast horizon. Lack of disease awareness in some underdeveloped regions is leading to an expanding base of patients in the region. This, coupled with increasing healthcare spending, presence of key manufacturers, such as Zydus Cadila, Novartis, and Sun Pharmaceuticals, and growing product approvals, is expected to propel the market in APAC. Increasing demand for target drug for disease reversal is poised to augment the regional markets during the forecast period.

Competitive Landscape

Manufacturers offering generic versions dominate the global hydroxychloroquine drugs market. Companies are focusing on building generic chemical entities and innovative molecules to consolidate their foothold. Some of the prominent market participants are DR. REDDY'S LABORATORIES LTD, Laurus Labs Limited, Lupin, Mylan NV, Novartis International AG, Sanofi SA, Sun Pharmaceutical Industries Ltd, Teva Pharmaceuticals USA Inc., and Zydus Pharmaceuticals.

The introduction of generic versions and the strong clinical pipeline is anticipated to increase competition in the market. For instance, in April 2020, Zydus Cadila and Ipca Labs have backward integrated HCQ making capability with the aim to increase production capacity by 5-6 times to 70 MT per month thereby, expanding the range of treatment options for the millions of patients living with target diseases.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Disease Outbreaks Such As Coronavirus Disease (COVID 19)
    • 4.2.2 High prevalence of Malaria and Rheumatoid Arthritis
    • 4.2.3 Increasing Product Launches and Approvals
    • 4.2.4 Expanding Application of Hydroxychloroquine in Various Therapeutic Conditions
  • 4.3 Market Restraints
    • 4.3.1 Global Shortage of Hydroxychloroquine
    • 4.3.2 Poor Healthcare Accessibility in Low Income Countries
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Application
    • 5.1.1 Coronavirus Disease (COVID-19)
    • 5.1.2 Malaria
    • 5.1.3 Lupus Erythematosus
    • 5.1.4 Rheumatoid Arthritis
  • 5.2 By distribution Channel
    • 5.2.1 Online Pharmacy
    • 5.2.2 Hospital Pharmacy
    • 5.2.3 Retail Pharmacy
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 DR. REDDY'S LABORATORIES LTD
    • 6.1.2 Laurus Labs Limited,
    • 6.1.3 Lupin
    • 6.1.4 Mylan NV
    • 6.1.5 Novartis International AG
    • 6.1.6 Sanofi SA
    • 6.1.7 Sun Pharmaceutical Industries Ltd
    • 6.1.8 Teva Pharmaceuticals USA Inc.
    • 6.1.9 Zydus Pharmaceuticals

7 MARKET OPPORTUNITIES AND FUTURE TRENDS